Research programme: allosteric modulators - Addex Therapeutics

Drug Profile

Research programme: allosteric modulators - Addex Therapeutics

Alternative Names: A2A PAM; ADX 68692; ADX 71441; ADX-71743; ADX-71943; ADX-92639; Cpd 23; FSH NAM; FSHR/LHR NAM for sex hormone dependent tumours and reproductive system disorders - Addex Therapeutics; GABA-BR PAM for overactive bladder - Addex; IL1R1 NAM (CD121a); mGluR2 NAM; mGluR3 NAM; mGluR3 PAM; mGluR7 NAM; Orexin 2R NAM; TNFR1 NAM (CD120a); TNFR1 NAM (TNF receptor superfamily); TrkB PAM (RTK superfamily) - Addex Therapeutics; TrkB receptor agonists - Addex; TrkB receptor modulators - Addex; TrkBPAM

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Pharmaceuticals; Addex Therapeutics; National Institute on Drug Abuse
  • Class Analgesics; Neuroprotectants; Neuropsychotherapeutics; Small molecules; Urologics
  • Mechanism of Action Adenosine A2 receptor modulators; Chorionic gonadotropin modulators; Follicle stimulating hormone modulators; GABA B receptor agonists; Interleukin 2 receptor modulators; Luteinising hormone modulators; Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 7 modulators; Metabotropic glutamate receptor modulators; Orexin receptor type 2 modulators; Ovarian follicle modulators; TrkB receptor agonists; TrkB receptor modulators; Tumour necrosis factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alcoholism; Alzheimer's disease; Amyotrophic lateral sclerosis; Autistic disorder; Charcot-Marie-Tooth disease; Cocaine abuse; Drug abuse; Endometriosis; Fragile X syndrome; Major depressive disorder; Muscle spasticity; Overactive bladder; Pain; Polycystic ovary syndrome; Urinary incontinence; Visceral pain
  • Research Anxiety disorders; Huntington's disease; Parkinson's disease; Post-traumatic stress disorders
  • Discontinued Gastro-oesophageal reflux; Gout; Inflammatory bowel diseases; Osteoarthritis; Osteoporosis; Pregnancy; Prostate cancer; Psoriasis; Rheumatoid arthritis; Sleep disorders

Most Recent Events

  • 03 Oct 2017 Addex Therapeutics plans phase I development for Cocaine abuse in the first half of 2018
  • 09 May 2017 Interim pharmacodynamics data from preclinical study in Visceral pain released by Addex Therapeutics
  • 31 Jan 2017 Addex Therapeutics receives regulatory approval to initiate phase I clinical trial for ADX 71441
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top